ARHGAP11A and nonpapillary renal cell carcinoma: Further analyses showed that a higher proportion of ccRCC patients responded to ICIs therapy in the ARHGAP11A low-level group, and the “TRUE-responder” group had a lower ARHGAP11A level (Figure 7D,E).